Inbiomotion
A personalized medicine company developing biomarkers that can predict bone metastasis in cancers.
Launch date
Employees
Market cap
-
Enterprise valuation
$9—13m (Dealroom.co estimates Mar 2016.)
Company register number B65446403
Barcelona Catalonia (HQ)
Financials
Estimates*
| EUR | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|---|
| Revenues | <1m | <1m | - | - | - | - | - |
| % growth | - | 631 % | - | - | - | - | - |
| EBITDA | (<1m) | (<1m) | (<1m) | (<1m) | (<1m) | (<1m) | (<1m) |
| % EBITDA margin | (5509 %) | (820 %) | - | - | - | - | - |
| Profit | (<1m) | (<1m) | (<1m) | (<1m) | (<1m) | (<1m) | (<1m) |
| % profit margin | (6068 %) | (864 %) | - | - | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Spinout | ||
$2.6m | Seed | ||
€50.0k | Grant | ||
$2.2m | Series B | ||
N/A | Late VC | ||
* | N/A | - | |
| Total Funding | $4.9m | ||
Related Content
Recent News about Inbiomotion
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.